Martin Tobi

Dr. Martin Tobi

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2008 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
RMRama MarepaIly
Rama MarepaIly
DMDan Micheals
Dan Micheals
ASAndrew Sloan
Andrew Sloan
JHJames Hatfield
James Hatfield
VAVolkan Adsay
Volkan Adsay
MTMartin Tobi
Martin Tobi

20 January 2007 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
JAJamil Akhras
Jamil Akhras
PPPragnesh Patel
Pragnesh Patel
MTMartin Tobi
Martin Tobi

22 September 2012 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
MTMartin Tobi
Martin Tobi
MKMijin Kim
Mijin Kim
DWDouglas H. Weinstein
Douglas H. Weinstein
MRMary Ann Rambus
Mary Ann Rambus
JHJames Hatfield
James Hatfield
SFSuzanne Fligiel
Suzanne Fligiel

25 June 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
MTMartin Tobi
Martin Tobi
DCDiptaraj S. Chaudhari
Diptaraj S. Chaudhari
Elizabeth P RyanElizabeth P Ryan
Elizabeth P Ryan
NRNoreen F. Rossi
Noreen F. Rossi
OKOrena Koka
Orena Koka
MAMariana Angoa-Perez
Mariana Angoa-Perez
While there are many postulates for the etiology of post-viral chronic fatigue and other symptomatology, little is known. We draw on our past experience of these syndromes to devise means which can expose the primary players of this malady in terms of a panoply participating biomolecules and the state of the stool microbiome. Using databases established from a large dataset of patients at risk of colorectal cancer who were followed longitudinally over 3 decades, and a smaller database dedicated to building a Long PASC cohort (Post-Acute Sequelae of COVID-19), we were able to ascertain factors that predisposed patients to (and resulted in) significant changes in various biomarkers, i.e., the stool microbiome and serum cytokine levels, which we verified by collecting stool and serum samples. There were significant changes in the stool microbiome with an inversion from the usual Bacillota and Bacteroidota species. Serum cytokines showed significant differences in MIP-1β versus TARC (CC chemokine ligand 17) in patients with either PASC or COVID-19 (p < 0.02); IL10 versus IL-12p70a (p < 0.02); IL-1b versus IL-6 (p < 0.01); MCP1 versus TARC (p < 0.03); IL-8 versus TARC (p < 0.002); and Eotaxin3 versus TARC (p < 0.004) in PASC. Some changes were seen solely in COVID-19, including MDC versus MIP-1α (p < 0.01); TNF-α versus IL-1-β (p < 0.06); MCP4 versus TARC (p < 0.0001). We also show correlates with chronic fatigue where an etiology was not identified. These findings in patients with positive criteria for PASC show profound changes in the microbiome and serum cytokine expression. Patients with chronic fatigue without clear viral etiologies also have common associations, including a history of tonsillectomy, which evokes a likely immune etiology.

Verified
Journal Article
Open access
PDF file
MTMartin Tobi
Martin Tobi
FAFadi Antaki
Fadi Antaki
MRMary Rambus
Mary Rambus
YYYu-Xiao Yang
Yu-Xiao Yang
DKDavid Edward Kaplan
David Edward Kaplan
BMBenita McVicker
Benita McVicker
Given the need to improve the sensitivity of non-invasive methods to detect colorectal neoplasia, particularly adenomas, we compared a fecal test using a monoclonal antibody (Mab) raised against constituents of colonic adenomas designated Adnab-9 (Adenoma Antibody 9), recognizing an N-linked 87 kDa glycoprotein, to gFOBT, which is shown to reduce CRC mortality. p87 immunohistochemistry testing is significantly more sensitive (OR 3.64[CI 2.37–5.58]) than gFOBT (guaiac-based fecal occult blood test) for adenomas (<3 in number), advanced adenomas (OR 4.21[CI 2.47–7.15]), or a combination of the two (OR 3.35[CI 2.47–4.53]). p87 immunohistochemistry shows regional Paneth cell (PC) expression mainly in the right-sided colon and is significantly reduced in the ceca of African Americans (p < 0.0001). In a subset of patients, we obtained other body fluids such as urine, colonic effluent, and saliva. Urine tests (organ-specific neoantigen) showed a significant difference for advanced adenomas (p < 0.047). We conclude that fecal p87 testing is more sensitive than gFOBT and Adnab-9 and could be used to better direct the colonoscopy screening effort.

Verified
Journal Article
Open access
PDF file
MKMurali R Kuracha
Murali R Kuracha
VGVenkatesh Govindarajan
Venkatesh Govindarajan
BLBrian W. Loggie
Brian W. Loggie
MTMartin Tobi
Martin Tobi
BMBenita McVicker
Benita McVicker
The phosphatidylinositol (PI3K)/AKT/mTOR axis represents an important therapeutic target to treat human cancers. A well-described downstream target of the PI3K pathway is the forkhead box O (FOXO) transcription factor family. FOXOs have been implicated in many cellular responses, including drug-induced resistance in cancer cells. However, FOXO-dependent acute phase resistance mediated by pictilisib, a potent small molecule PI3K inhibitor (PI3Ki), has not been studied. Here, we report that pictilisib-induced adaptive resistance is regulated by the FOXO-dependent rebound activity of receptor tyrosine kinases (RTKs) in mucinous colorectal adenocarcinoma (MCA) cells. The resistance mediated by PI3K inhibition involves the nuclear localization of FOXO and the altered expression of RTKs, including ErbB2, ErbB3, EphA7, EphA10, IR, and IGF-R1 in MCA cells. Further, in the presence of FOXO siRNA, the pictilisib-induced feedback activation of RTK regulators (pERK and pAKT) was altered in MCA cells. Interestingly, the combinational treatment of pictilisib (Pi3Ki) and FOXO1i (AS1842856) synergistically reduced MCA cell viability and increased apoptosis. These results demonstrate that pictilisib used as a single agent induces acute resistance, partly through FOXO1 inhibition. Therefore, overcoming PI3Ki single-agent adaptive resistance by rational design of FOXO1 and PI3K inhibitor combinations could significantly enhance the therapeutic efficacy of PI3K-targeting drugs in MCA cells.